Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John E. Janik, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
38 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia
- Scientia Clinical Research
Randwick, New South Wales, Australia
- Greenslopes Private Hospital
Brisbane, Queensland, Australia
- Austin Hospital
Heidelberg, Victoria, Australia
- Linear Clinical Research
Perth, Western Australia, Australia
- Cha Centre Hospitalier de L'Ardenne
Libramont, Chevigny, Belgium
- Saint Augustinus Hospital
Antwerp, Belgium
- Chu Brugmann
Brussels, Belgium
- Cliniques Universitaires Saint-Luc
Brussels, Belgium
- Institut Jules Bordet
Brussels, Belgium
- Mi Kryviy Rih Center of Dnipropetrovsk Regional Council
Charleroi, Belgium
- Ghent University Hospital
Ghent, Belgium
- Az Groeninge
Kortrijk, Belgium
- Hospital Clinic I Provincial
Barcelona, Spain
- Hospital Clinico Y Provincial de Barcelona
Barcelona, Spain
- Hospital Vall de Hebron
Barcelona, Spain
- Institut Catala D'Oncologia-Badalona
Barcelona, Spain
- Hospital Reina Sophia
Córdoba, Spain
- Hospital Hm Sanchinarro
Madrid, Spain
- Hospital Universitario Doce de Octubre
Madrid, Spain
- University Hospital Ramon Y Cajal
Madrid, Spain
- Clinica Universidad de Navarra (cun)
Pamplona, Spain
- Hospital Universitario Virgen del Rocio
Seville, Spain
- the Angeles Clinic and Research Institute
Los Angeles, California, United States
- University of Florida
Gainesville, Florida, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
- Washington University - Siteman Cancer Center
St Louis, Missouri, United States
- Hackensack University Medical Center
Hackensack, New Jersey, United States
- Memorial Sloan Kettering Cancer
New York, New York, United States
- the University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
- University of Oklahoma, Sarah Cannon Research Institute
Oklahoma City, Oklahoma, United States
- Providance Portland Medical Center
Portland, Oregon, United States
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
- University of Pittsburgh, Upmc Cancer Pavilion
Pittsburgh, Pennsylvania, United States
- Tennessee Oncology, Sarah Cannon Research Institute
Nashville, Tennessee, United States
- Bumc Mary Crowley Cancer Research Centers
Dallas, Texas, United States
- Md Anderson
Houston, Texas, United States
- Seattle Cancer Care Alliance
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Apr 2017
- Primary completion
- 9 Nov 2021
- Completion
- 9 Nov 2021
- Last update posted
- 14 Aug 2025
- Registered enrollment
- 145
- Registry id
- NCT03126110
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.